Psoriasis drug guselkumab under microscope in new immune study
NCT ID NCT04645355
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing how the drug guselkumab affects the immune system in people with two types of psoriasis: plaque and guttate. Twenty-five adults will receive guselkumab injections over 44 weeks. Researchers will measure changes in immune cells in the skin to understand how the drug works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Guselkumab (a biologic drug that blocks IL-23, given as an injection)
What this could lead to
If successful, this could help explain why guselkumab works for different types of psoriasis, potentially leading to more personalized treatment.
What could go wrong
This is a small, early-phase study with only 25 people, so results may not apply to everyone. It is not designed to prove long-term safety or cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UCSF Psoriasis and Skin Treatment Center
San Francisco, California, 94118, United States